NLRP3 protein inhibitors - Pipeline Insight, 2024

This “NLRP3 protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in NLRP3 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

NLRP3 protein inhibitors Understanding

NLRP3 protein inhibitors: Overview

The NLRP3 inflammasome regulates the release of pro-inflammatory cytokines in response to “danger signals,” including the presence of foreign or endogenous molecules that signal infection, tissue damage or metabolic imbalances. Chronic inflammation driven by improper activation of the NLRP3 inflammasome has been implicated in a wide array of diseases, including fibrotic, autoinflammatory and neurodegenerative diseases, as well as certain cancers. Small molecules that selectively inhibit NLRP3 have well-understood potential to address improper activation and treat chronic inflammation at the source, without broadly suppressing the immune system.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NLRP3 protein inhibitors R&D. The therapies under development are focused on novel approaches for NLRP3 protein inhibitors.

NLRP3 protein inhibitors Emerging Drugs Chapters

This segment of the NLRP3 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NLRP3 protein inhibitors Emerging Drugs

SB206: Novan SB206, is a topical antiviral gel for the treatment of viral skin infections. SB206 is currently being evaluated in B-SIMPLE4, a pivotal Phase 3 trial, for the treatment of treatment of molluscum contagiosum, a contagious skin infection caused by themolluscipoxvirus.

NT-0167: Nodthera NT-0167 is being evaluated in a Phase 1 clinical trial in healthy volunteers. Therapeutics that disrupt the NLRP3 inflammasome to inhibit damaging inflammatory processes have the potential to help patients with many chronic diseases. Nod Thera’s approach to selectively target the NLRP3 inflammasome without broadly suppressing the immune system is an enormously promising strategy for developing therapies that can helpthepatients

NLRP3 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NLRP3 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NLRP3 protein inhibitors

There are approx. 12+ key companies which are developing the NLRP3 protein inhibitors. The companies which have their NLRP3 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novan.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

NLRP3 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NLRP3 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NLRP3 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NLRP3 protein inhibitors drugs.

NLRP3 protein inhibitors Report Insights

• NLRP3 protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

NLRP3 protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing NLRP3 protein inhibitors drugs?
• How many NLRP3 protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NLRP3 protein inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NLRP3 protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NLRP3 protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novan
• Novartis
• Nodthera
• Zydus Cadila
• Ventus Therapeutics
• Monte Rosa Therapeutics
• Roche
• Inflazome
• Ionis Pharmaceuticals
• TWi Biotechnology

Key Products

• SB206
• DFV 890
• NT 0167
• ZYIL-1
• SB 206

Research programme: NEK7 targetting anti-inflammatories- Research programme: NLRP3 inflammasome inhibitors

• IZD-334

Research programme: NLRP3 antisense oligonucleotides- RG 6418

• Diacerein
• IZD-174

This product will be delivered within 1-3 business days.